OncoSec Announces Clinical Data of the KEYNOTE-695 Trial Assessing TAVO(TM)-EP in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Melanoma Refractory to anti-PD-1 Treatment
We use cookies to improve your experience on our site, to show you personalized advertising, and as otherwise described in our Cookie Policy
. To find out more, read our
Privacy Policy
and our
Cookie Policy.